Open company graph database — free web & API
Login

Torii Pharmaceutical Co., Ltd.

鳥居薬品株式会社
Ticker
—
Listed market
—
Country
Japan
Employees (consolidated)
619
Related companies
19
§01

Basic information

BASIC
Head office
3-4-1 Nihonbashi Honcho, Chuo-ku, Tokyo, Torii Nihonbashi Building
Chief executive
Shinya Kondo
Capital
5,190,000,000 JPY (51 100 millionJPY)
Employees (non-consolidated)
Employees (consolidated)
619 people
Start date
1921-11-01
End date
§02

Websites

1 DOMAINS
§03

Business

1
Manufacture and sale of pharmaceuticals
§04

Related companies

19 COMPANIES
Company name Group Parent Subsidiary Customer Supplier Alliance Bank Shareholder
Japan Tobacco Inc.
Group Parent
SHIONOGI Group
Group
Verrica Pharmaceuticals Inc.
Group
Mos Food Services Inc.
Group
Japan Custody Bank Inc.
Group
Mitsubishi UFJ Bank Ltd.
Group
Shionogi & Co., Ltd.
Group
Japan Master Trust Bank Ltd.
Group
Mizuho Bank, Ltd.
Group
Mizuho Securities Co., Ltd.
Group
Toray Industries, Inc.
Group
Cultural Broadcasting Co., Ltd.
Group
Nomura Securities Co.,Ltd.
Group
Nomura Asset Management
Group
BioCryst Pharmaceuticals, Inc.
Group
Keryx Biopharmaceuticals, Inc.
Group
Tokyo Stock Exchange, Inc.
Customer
エフィッシモ キャピタル マネージメント ピーティー イー エルティーディー
Shareholder
Deloitte Tohmatsu LLC
Bank
Names without a link are companies not yet registered in OpenBizGraph
§05

Network

NETWORK
Drag to move · click to open
§06

History

29 EVENTS

Tokuhei Torii established the Western medicine import business 'Utenoya' in Sakaimachi, Yokohama CitySources

Since its founding in 1872, we continue to transform ourselves with flexible ideas and quick actions while valuing the trust we have built.Sources

Established a pharmaceutical testing laboratory and started manufacturing and selling sealed productsSources

Opened a branch office (current headquarters) in Nihonbashi Honcho, TokyoSources

Established Torii Shoten Co., Ltd.Sources

Merged with Torii Seiyaku Co., Ltd. and changed the trade name to Torii Pharmaceutical Co., Ltd.Sources

Launched allergy diagnostic therapeutic drug 'Allergen Extract'Sources

Registered our stocks as over-the-counter stocks with the Tokyo Stock ExchangeSources

Completed Sakura Factory in Sakura City, Chiba PrefectureSources

Completed the current headquarters buildingSources

Listed on the Tokyo Stock Exchange Second SectionSources

Launched external corticosteroid 'Antevate Ointment and Cream'Sources

Reclassified to the First Section of the Tokyo Stock ExchangeSources

Japan Tobacco Inc. (JT) acquired a majority of our sharesSources

Established a collaboration system where sales functions are integrated into our company and research and development functions are concentrated in JTSources

Launched oral antipruritic agent 'Remitch Capsule' (manufactured and sold by Toray Industries, Inc., approved for sale)Sources

Launched hyperphosphatemia treatment 'Riona Tablets' (manufactured and sold by JT, approved for sale)Sources

Launched allergen immunotherapy drug 'Shidatoren Cedar Pollen Sublingual Solution' for cedar pollen allergySources

Launched allergen immunotherapy drug 'Miticure Dust Mite Sublingual Tablets' for dust mite allergySources

Launched allergen immunotherapy drug 'Shidacure Cedar Pollen Sublingual Tablets' for cedar pollen allergySources

Launch of the externally used Janus kinase (JAK) inhibitor "Collecithum Ointment" (JT manufacturing and sales approval obtained)Sources

Transfer of Sakura Factory to Iwaki Pharmaceutical Co., Ltd.Sources

Launch of the renal anemia treatment drug "Enaroil Tablets" (JT manufacturing and sales approval obtained)Sources

Launch of the hereditary angioedema attack suppressor plasma kallikrein inhibitor "Oradeo Capsules" (Manufactured and sold by Ophan Pacific Corporation, approval obtained)Sources

Transition from the First Section of the Tokyo Stock Exchange to the Prime Market due to review of market classificationSources

Launch of atopic dermatitis treatment and ordinary psoriasis treatment "VitaMark Cream" (JT manufacturing and sales approval obtained)Sources

Becoming a wholly owned subsidiary of Shionogi & Co., Ltd.Sources

Starting from September 1, 2025, we began a new journey as a member of the Shionogi Group.Sources

Viral warts treatment drug "Ycans® External Liquid 0.71%"Sources

§07

News

0 ARTICLES

There is no news.

§08

Public records

GOV
National Tax Agency basic information4010001052143
Source: National Tax Agency Corporate Number Publication Site, basic three itemsSources
Trade name
鳥居薬品株式会社
Trade name (kana)
トリイヤクヒン
Name in English
Corporation type
301
Address
〒103-0023 東京都中央区日本橋本町3丁目4番1号
Postal code
1030023
Prefecture code
13
City code
102
Address outside Japan
Prefecture in English
City in English
Address outside Japan in English
Corporate number assignment date
2015-10-05
Update date
2018-04-16
Change date
2015-10-05
Registry closure date
Reason for registry closure
Successor corporate number
Details of the change
Latest record
1
Excluded from search
0
Processing type
01
Correction type
1
Trade name image ID
Address image ID
Sequence number
1718466
METI gBizINFO4010001052143
Source: gBizINFO (Ministry of Economy, Trade and Industry)Sources
Corporate number
4010001052143
Trade name
鳥居薬品株式会社
Trade name (kana)
トリイヤクヒン
Trade name (alphabet)
Registry closure date
Reason for registry closure
Registered address
東京都中央区日本橋本町3丁目4番1号
Postal code
1030023
Prefecture
東京都
Prefecture code
13
City or district
中央区
City code
102
Street address
日本橋本町3丁目4番1号
Organisation type
301
Processing type
01
Correction type
1
Status
Representative
代表取締役社長  近藤 紳雅
Capital
5190000000
Employees
595
Employees (male)
Employees (female)
Business summary
医薬品の製造・販売
Website URL
http://www.torii.co.jp/
Year founded
Business category
E:製造業
Date established
Unified government qualification - grade
Unified government qualification - business items
Update date
2018-04-16
Key information
4010001052143
§09

Sources & updates

SOURCES
↑